[go: up one dir, main page]

MXPA05013340A - Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. - Google Patents

Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.

Info

Publication number
MXPA05013340A
MXPA05013340A MXPA05013340A MXPA05013340A MXPA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A
Authority
MX
Mexico
Prior art keywords
growth hormone
subject
methods
delivery
blood plasma
Prior art date
Application number
MXPA05013340A
Other languages
English (en)
Inventor
Shyam Vangala
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of MXPA05013340A publication Critical patent/MXPA05013340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen formulaciones farmaceuticas que comprenden por lo menos una hormona del crecimiento y uno o mas agentes incrementadores de liberacion intranasales para la liberacion mucosal nasal incrementada de la hormona del crecimiento. En un aspecto, las formulaciones y metodos de liberacion intranasales proporcionan liberacion incrementada de la hormona del crecimiento al plasma sanguineo, por ejemplo, rindiendo una concentracion maxima (Cmax) de la hormona del crecimiento en una vena portal hepatica o un plasma sanguineo del sujeto que es 20% o mas grande comparado con una concentracion maxima de la hormona del crecimiento en la vena portal hepatica o del pasma sanguineo del sujeto despues de la administracion al sujeto de una misma concentracion o dosis de la hormona del crecimiento al sujeto por inyeccion subcutanea. Las formulaciones y los metodos de ejemplo de la invencion utilizan la hormona humana del crecimiento como la hormona.
MXPA05013340A 2003-06-09 2004-06-01 Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. MXPA05013340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47740303P 2003-06-09 2003-06-09
PCT/US2004/017632 WO2005004895A2 (en) 2003-06-09 2004-06-01 Compositions and methods for enhanced mucosal delivery of growth hormone

Publications (1)

Publication Number Publication Date
MXPA05013340A true MXPA05013340A (es) 2006-03-09

Family

ID=34061913

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013340A MXPA05013340A (es) 2003-06-09 2004-06-01 Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.

Country Status (6)

Country Link
US (1) US20050031549A1 (es)
EP (1) EP1643970A2 (es)
JP (1) JP2007500243A (es)
CA (1) CA2528465A1 (es)
MX (1) MXPA05013340A (es)
WO (1) WO2005004895A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
DK1888103T3 (da) * 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
WO2007003936A1 (en) * 2005-07-02 2007-01-11 Arecor Limited Stable aqueous systems comprising proteins
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
WO2007022345A2 (en) 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8058253B2 (en) * 2006-07-06 2011-11-15 Vgx Pharmaceuticals, Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
KR20100047866A (ko) * 2007-07-11 2010-05-10 애로반스, 인코포레이티드 약제학적 폴리펩타이드 건조 분말 에어로졸 제형 및 이의 제조 방법
EP2457590B1 (en) * 2008-05-01 2014-12-24 Arecor Limited Protein formulation
EP2328607A1 (en) * 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
MX2011002688A (es) * 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
WO2010080406A1 (en) * 2008-12-18 2010-07-15 Adrem Biotech, Inc. Method for treating rhinitis and sinusitis by rhamnolipids
US8592381B2 (en) 2008-12-18 2013-11-26 Rhamnopharma Inc. Method for treating rhinitis and sinusitis by rhamnolipids
US20120289465A1 (en) * 2009-11-25 2012-11-15 Gcbio Corp. Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases
EP2356998A1 (en) * 2010-02-17 2011-08-17 Université de Liège A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
WO2012154711A1 (en) * 2011-05-10 2012-11-15 Nestec S.A. Methods and compositions for promoting lean body mass growth
AU2012253701A1 (en) * 2011-05-10 2013-11-21 Nestec S.A. Methods and compositions for preserving lean body mass during weight loss
EP2739287B1 (en) * 2011-08-04 2017-07-05 Flexion Therapeutics, Inc. Corticosteroids for the treatment of joint pain
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG10201606775YA (en) 2012-02-15 2016-10-28 Aileron Therapeutics Inc Peptidomimetic macrocycles
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP5797227B2 (ja) * 2013-05-21 2015-10-21 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
US20180028767A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Topical spray system of halobetasol
BR112020001759A2 (pt) 2017-07-27 2020-07-21 Locus Ip Company, Llc composições para a intensificação da biodisponibilidade de produtos farmacêuticos, suplementos e substâncias ingeridas
WO2019133313A1 (en) 2017-12-28 2019-07-04 Locus Ip Company, Llc Oral health composition comprising purified biosurfactants and/or their derivatives
WO2020019033A1 (en) * 2018-07-25 2020-01-30 Palmer Raymond Denis Container for amylase inhibitor delivery
EP3958869A4 (en) 2019-05-10 2022-11-16 Locus IP Company, LLC COMPOSITIONS AND METHODS FOR TREATING BIOFILM-ASSOCIATED LUNG CONDITIONS
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US5122804A (en) * 1987-11-30 1992-06-16 Radar Data Systems, Inc. Method and apparatus for ground radar information display system
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus

Also Published As

Publication number Publication date
EP1643970A2 (en) 2006-04-12
WO2005004895A2 (en) 2005-01-20
CA2528465A1 (en) 2005-01-20
US20050031549A1 (en) 2005-02-10
WO2005004895A3 (en) 2005-09-15
JP2007500243A (ja) 2007-01-11

Similar Documents

Publication Publication Date Title
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
MXPA05006572A (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
AU2003301190A1 (en) Administration of capsaicinoids
PL1740154T3 (pl) Kompozycje insuliny o ulepszonym wchłanianiu
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
GEP20053473B (en) High Potency Dihydroergotamine Compositions
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL190838A0 (en) Intranasal administration of rapid acting insulin
IL153297A0 (en) Compounds and compositions for delivering active agents
IL135335A0 (en) Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
MY139203A (en) Pharmaceutical composition
EA200501105A1 (ru) Фармацевтическая композиция
AU4258101A (en) Combination therapies with vascular damaging activity
GB0130677D0 (en) Medicaments and novel compounds
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
GB2446341A (en) Method and system for transdermal drug delivery
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
SE0203817D0 (sv) New composition
TNSN05162A1 (en) Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
EA201000501A1 (ru) Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара

Legal Events

Date Code Title Description
FA Abandonment or withdrawal